Download PDFPDF

1389 GIGA-564 a third generation anti CTLA 4 with minimal ability to block CTLA 4 binding to B7 ligands has enhanced efficacy but reduced toxicity compared to ipilimumab in preclinical models
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address